Cocrystal Pharma, Inc. - COCP STOCK NEWS

Cocrystal Pharma (Nasdaq: COCP) has successfully completed its research obligations under its collaboration agreement with Merck within the initial two-year timeline. Merck will now assume full responsibility for the development of influenza A/B antiviral compounds discovered using Cocrystal's advanced technologies. This collaboration, praised for its efficacy, signifies a crucial step in addressing the urgent medical need for new influenza antivirals. Merck's ongoing development efforts will be crucial for these compounds’ future commercialization.

Cocrystal Pharma, Inc. (Nasdaq: COCP), a clinical-stage biotechnology company, announces that President Sam Lee, Ph.D., will present at the 3rd Annual reimagine Health Research Symposium on January 21, 2021. His presentation, titled “Application of structure-based drug design platform technology for developing broad spectrum COVID-19, influenza, and HCV antivirals,” will showcase the company's platform technology in antiviral drug discovery. Cocrystal recently selected a lead compound for its COVID-19 program, advancing its efforts against coronaviruses.

Cocrystal Pharma (Nasdaq: COCP), a clinical-stage biotechnology company, will present at NobleCon17 on January 19, 2021, at 2:15 p.m. ET. This annual investor conference focuses on innovative pharmaceutical developments, specifically novel antiviral therapeutics. The live presentation can be accessed at www.noblecon17.com, with a high-definition video available post-event on Cocrystal's website starting January 20, 2021. Cocrystal specializes in antiviral drugs targeting influenza, hepatitis C, coronaviruses, and noroviruses.

BOTHELL, Wash., Jan. 5, 2021 – Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that management will present at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The presentation will be accessible on the company’s website starting January 11, 2021, at 6:00 a.m. Eastern time. CEO Gary Wilcox highlighted the company's progress in advancing its pipeline of novel antiviral compounds during 2020 and expressed anticipation for discussing upcoming milestones at the conference.

For more details about Cocrystal, visit www.cocrystalpharma.com.

Cocrystal Pharma, Inc. (Nasdaq: COCP) has selected CDI-45205 as its lead compound for developing antiviral treatments targeting coronaviruses, including SARS-CoV-2. This compound, acquired under an exclusive licensing agreement from Kansas State University, has shown promise in preclinical studies. Cocrystal plans to initiate API synthesis and IND-enabling studies for CDI-45205, which may be delivered through injection or inhalation. The company also aims to develop additional oral coronavirus inhibitors using its proprietary technology. These efforts are viewed as complementary to existing COVID-19 vaccines.

Cocrystal Pharma (COCP) reported its Q3 2020 results, revealing a revenue of $489,000, slightly down from $492,000 year-over-year. The company closed the quarter with $31.8 million in cash, enabling the expansion of COVID-19 and Influenza A programs. Key developments include positive in vitro data for lead molecule CC-42344 against influenza and ongoing collaborations with Merck for influenza antiviral agents. Net losses increased to $2.67 million, reflecting higher R&D expenses due to COVID-19 initiatives. The company anticipates advancing its IND-enabling studies and initiating Phase 1 trials in 2021.

Cocrystal Pharma, Inc. (NASDAQ: COCP) announced that Dr. Gary Wilcox and Dr. Sam Lee will present at the World Antiviral Conference on November 12, 2020, at 1:20 PM EST. Their presentation will cover novel antiviral therapeutics targeting coronaviruses and influenza A strains. Cocrystal's proprietary technology aims to develop broad-spectrum influenza antivirals and COVID-19 treatments, with promising in vitro activity against SARS-CoV-2. The company expects to choose its lead preclinical molecule by year-end 2020.

Cocrystal Pharma, Inc. (NASDAQ: COCP) announced a presentation at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 12:00 PM EST. The management team will also hold virtual one-on-one meetings with registered investors at the event. A live video webcast will be accessible through the company's website, with a replay available two hours post-event.

Cocrystal Pharma (NASDAQ: COCP) announced promising in vitro data for its influenza A drug candidate CC-42344. The compound demonstrated antiviral activity against a resistant H1N1 strain, retaining a potency of 0.5 nM. Ongoing IND-enabling studies show a favorable safety profile, with a no adverse effect level exceeding 1,000 mg/kg in rat and dog studies. Cocrystal plans to finalize the Phase 1 study protocol and begin clinical trials in 2021, aiming to address concerns over seasonal and pandemic influenza.